BR112019007927A2 - conjugados de polimixina ? oligômeros de alginato - Google Patents
conjugados de polimixina ? oligômeros de alginatoInfo
- Publication number
- BR112019007927A2 BR112019007927A2 BR112019007927A BR112019007927A BR112019007927A2 BR 112019007927 A2 BR112019007927 A2 BR 112019007927A2 BR 112019007927 A BR112019007927 A BR 112019007927A BR 112019007927 A BR112019007927 A BR 112019007927A BR 112019007927 A2 BR112019007927 A2 BR 112019007927A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- polymyxin
- alginate oligomers
- alginate oligomer
- bacterial
- Prior art date
Links
- 229940072056 alginate Drugs 0.000 title abstract 3
- 229920000615 alginic acid Polymers 0.000 title abstract 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title abstract 2
- 108010040201 Polymyxins Proteins 0.000 title abstract 2
- 235000010443 alginic acid Nutrition 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617860.0A GB201617860D0 (en) | 2016-10-21 | 2016-10-21 | Polymyxin-alginate oligomer conjugates |
| GBGB1714710.9A GB201714710D0 (en) | 2017-09-13 | 2017-09-13 | Polymyxin-alginate oligomer conjugates |
| PCT/EP2017/076927 WO2018073449A1 (en) | 2016-10-21 | 2017-10-20 | Polymyxin-alginate oligomer conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019007927A2 true BR112019007927A2 (pt) | 2019-07-02 |
Family
ID=60186268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019007927A BR112019007927A2 (pt) | 2016-10-21 | 2017-10-20 | conjugados de polimixina ? oligômeros de alginato |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190328833A1 (https=) |
| EP (1) | EP3528830B1 (https=) |
| JP (1) | JP2020503253A (https=) |
| KR (1) | KR20190072579A (https=) |
| CN (1) | CN109843315A (https=) |
| AU (1) | AU2017345295A1 (https=) |
| BR (1) | BR112019007927A2 (https=) |
| CA (1) | CA3040795A1 (https=) |
| DK (1) | DK3528830T3 (https=) |
| ES (1) | ES2933983T3 (https=) |
| FI (1) | FI3528830T3 (https=) |
| RU (1) | RU2019109719A (https=) |
| WO (1) | WO2018073449A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115003311B (zh) * | 2019-12-14 | 2024-04-19 | 乔杜里·马努 | 降低多器官毒性的多元药物制剂 |
| WO2021150792A1 (en) * | 2020-01-21 | 2021-07-29 | Micurx Pharmaceuticals, Inc. | Novel compounds and composition for targeted therapy of kidney-associated cancers |
| US12037631B2 (en) * | 2020-10-06 | 2024-07-16 | City University Of Hong Kong | System and method for detecting a target enzyme |
| CN113069556B (zh) * | 2021-04-12 | 2022-04-08 | 青岛大学附属医院 | 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法 |
| CN113081956A (zh) * | 2021-04-12 | 2021-07-09 | 青岛大学附属医院 | 一种氧化海藻酸钠改性的那他霉素滴眼液及其制备方法 |
| JP7755347B2 (ja) * | 2021-07-21 | 2025-10-16 | シャンハイ ミクウルク ファーマシューティカル シーオー．エルティーディー | 腎癌の標的治療のための新規化合物及び組成物 |
| US20250109171A1 (en) * | 2021-07-21 | 2025-04-03 | Shanghai MICURX Pharmaceuticals Co., Ltd. | Compounds and compositions for targeted therapy of renal diseases |
| CN114009731B (zh) * | 2021-11-05 | 2024-01-02 | 恒枫食品科技有限公司 | 一种茶风味基料及其制备方法、应用 |
| CN114752535A (zh) * | 2022-05-16 | 2022-07-15 | 北京昊峰节能环保科技有限公司 | 一种总石油烃污染地下水生物修复剂及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB976301A (en) * | 1960-10-27 | 1964-11-25 | Calmic Ltd | Preparation and use of alginates |
| ES2063326T3 (es) * | 1989-11-15 | 1995-01-01 | Sandoz Ltd | Conjugados de polimixina. |
| US5177059A (en) * | 1989-11-15 | 1993-01-05 | Sandoz Ltd. | Polymyxin B conjugates |
| GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
| US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
| HUE034051T2 (en) * | 2007-11-27 | 2018-01-29 | Algipharma As | Use of alginate-containing oligomers to combat biofilms |
| ES2444541T3 (es) * | 2009-06-03 | 2014-02-25 | Algipharma As | Oligómeros de alginato para usar para superar la multirresistencia a fármacos en bacterias |
-
2017
- 2017-10-20 AU AU2017345295A patent/AU2017345295A1/en not_active Abandoned
- 2017-10-20 CN CN201780065109.5A patent/CN109843315A/zh active Pending
- 2017-10-20 BR BR112019007927A patent/BR112019007927A2/pt not_active IP Right Cessation
- 2017-10-20 DK DK17791037.9T patent/DK3528830T3/da active
- 2017-10-20 EP EP17791037.9A patent/EP3528830B1/en active Active
- 2017-10-20 FI FIEP17791037.9T patent/FI3528830T3/fi active
- 2017-10-20 JP JP2019521049A patent/JP2020503253A/ja active Pending
- 2017-10-20 ES ES17791037T patent/ES2933983T3/es active Active
- 2017-10-20 RU RU2019109719A patent/RU2019109719A/ru unknown
- 2017-10-20 KR KR1020197014050A patent/KR20190072579A/ko not_active Abandoned
- 2017-10-20 WO PCT/EP2017/076927 patent/WO2018073449A1/en not_active Ceased
- 2017-10-20 US US16/343,568 patent/US20190328833A1/en not_active Abandoned
- 2017-10-20 CA CA3040795A patent/CA3040795A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190072579A (ko) | 2019-06-25 |
| FI3528830T3 (fi) | 2023-01-13 |
| RU2019109719A (ru) | 2020-11-24 |
| DK3528830T3 (da) | 2022-12-19 |
| RU2019109719A3 (https=) | 2021-02-20 |
| CA3040795A1 (en) | 2018-04-26 |
| ES2933983T3 (es) | 2023-02-15 |
| CN109843315A (zh) | 2019-06-04 |
| WO2018073449A1 (en) | 2018-04-26 |
| EP3528830A1 (en) | 2019-08-28 |
| JP2020503253A (ja) | 2020-01-30 |
| AU2017345295A1 (en) | 2019-05-02 |
| EP3528830B1 (en) | 2022-10-05 |
| US20190328833A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019007927A2 (pt) | conjugados de polimixina ? oligômeros de alginato | |
| BR112019007928A2 (pt) | conjugados de bacitracina-oligômero de alginato | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| CY1121416T1 (el) | Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| MA37206B1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| UA122346C2 (uk) | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ | |
| WO2019136180A3 (en) | Heteroduplex nucleic acid molecules and uses thereof | |
| BR112018006016A2 (pt) | intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
| BR112019000453A2 (pt) | combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas | |
| NO20090251L (no) | Camptotecinderivater med antitumoraktivitet | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| LT3866767T (lt) | Farmacinė kompozicija, skirta peroraliniam vartojimui, apimanti aminopirimidino darinį arba jo druską | |
| CN110382500A (zh) | 用于ido和tdo双重抑制剂的脲类化合物 | |
| EA201891419A1 (ru) | Пептид-олигонуклеотидные конъюгаты | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112017004796A2 (pt) | método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação | |
| PH12021551223A1 (en) | Decarboxylase inhibitors for treating parkinson`s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2745 DE 15-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |